Fate Therapeutics, Inc. (NASDAQ:FATE) is on recovery track with 162.15% gain from a 1-year low price of $6.5. The company lost -3.13% to attain the price of $17.04 on 01/11/2019. Throughout the recent session, the prices were hovering between $16.97 and $17.8. These shares are 8.16% off its target price of $18.43 and the current market capitalization stands at $1.13B. The recent change has given its price a 20.89% lead over SMA 50 and -5.23% deficit over its 52-week high. The stock witnessed 4.22% gains, 21.45% gains and 42.95% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found FATE’s volatility during a week at 7.6% and during a month it has been found around 9.99%.Fate Therapeutics, Inc. (FATE) Top Holders
Institutional investors currently hold around $936 million or 88.8% in FATE stock. Look at its top three institutional owners. Redmile Group, Llc owns $180.22 million in Fate Therapeutics, Inc., which represents roughly 15.95% of the company’s market cap and approximately 19.25% of the institutional ownership. Similar statistics are true for the second largest owner, Fmr Llc, which owns 7,637,402 shares of the stock are valued at $130.14 million. The third largest holder is Franklin Resources Inc, which currently holds $91.31 million worth of this stock and that ownership represents nearly 8.08% of its market capitalization.Fate Therapeutics, Inc. 13F Filings
At the end of September reporting period, 72 institutional holders increased their position in Fate Therapeutics, Inc. (NASDAQ:FATE) by some 13,450,757 shares, 41 decreased positions by 1,564,492 and 18 held positions by 39,891,856. That puts total institutional holdings at 54,907,105 shares, according to SEC filings. The stock grabbed 28 new institutional investments totaling 4,686,520 shares while 14 institutional investors sold out their entire positions totaling 316,384 shares.Fate Therapeutics, Inc. (NASDAQ:FATE) Insider Trades
Multiple company employees have indulged in significant insider trading. Fate Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that General Counsel and Secretary Tahl Cindy has sold 25,000 shares of Fate Therapeutics, Inc. (FATE) in trading session dated Jan. 07, 2019. These shares are worth $400,000 and were traded at $16 each. The SEC filing shows that Nashat Amir performed a sale of 33,474 shares. The Director disposed these shares by way of transaction on Dec. 20, 2018. The company’s shares were given away at $12.25 per share worth to an income of some $410,057 on account of Nashat Amir.
Director, Nashat Amir, sold 91,210 common shares of Fate Therapeutics, Inc. (FATE) in the open market. In a transaction dated Dec. 19, 2018, the shares were put up for sale at an average price of $13.4, raking in a sum of $1,222,214. After this sale, 7,432,201 common shares of FATE are directly owned by the insider, with total stake valued at $126,644,705.
In the transaction dated Dec. 13, 2018, the great number of shares disposed came courtesy the Director; Nashat Amir disposed a total of 17,788 shares at an average price of $16.67, amounting to approximately $296,526. The insider now directly owns 7,792,566 shares worth $132,785,325.Fate Therapeutics, Inc. (FATE) Analyst Guide
Several analysts have released their opinion on Fate Therapeutics, Inc. (NASDAQ:FATE), with 4 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation.